Back to

Adam Sabow

Senior Partner, Chicago
Works with pharmaceutical companies, biotechnology firms, global health institutions, and not for profits to support commercial and operational improvements in vaccines, biologics, and sterile injectables

About Adam

Adam is a leader in McKinsey’s Life Sciences and Global Public Health practices and he leads our Social Sector Practice in the Americas. He has worked extensively with pharmaceutical companies, biotechnology firms, not for profits, and government agencies in many parts of the world. His particular focus is on supporting commercial and operational improvement in the vaccines, biologics, and sterile-injectables arenas.

With his private-sector clients, he has helped shape these high-growth markets, defining strategies to continue the strong growth trajectory in vaccines, shaping the development of the biosimilars space from its early days, and evolving the performance of the sterile-injectables market.

In his work with global health institutions and not for profits, Adam has helped tackle some of the world’s most difficult problems: transforming the developing-country supply of vaccines, helping define new strategies to combat infectious diseases, and accelerating the introduction and uptake of new vaccines.

Adam speaks frequently at industry events, including providing the keynote addresses at BIO and the World Vaccine Congress and serving on World Health Organization expert consultations on a range of infectious disease topics.


Published work

When will the COVID-19 pandemic end?,” McKinsey & Company, August 2021

Getting to work: Employers’ role in COVID-19 vaccination,” McKinsey & Company, April 2021

When will the COVID-19 pandemic end?,” McKinsey & Company, March 2021

The risks and challenges of the global COVID-19-vaccine rollout,” McKinsey & Company, January 2021

COVID-19 vaccines meet 100 million uncertain Americans,” McKinsey & Company, December 2020

When will the COVID-19 pandemic end?,” McKinsey & Company, September 2020

Not the last pandemic: Investing now to reimagine public-health systems,” McKinsey & Company, July 2020

Refueling the innovation engine in vaccines,” McKinsey & Company, May 2019

Should sub-Saharan Africa make its own drugs?,” McKinsey & Company, January 2019

From science to operations: Questions, choices and strategies for success in biopharma” (PDF–790 KB), McKinsey & Company, September 2014


Kellogg School of Management, Northwestern University

Northwestern University
BA (with honors), economics and applied math